{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:32:07Z","timestamp":1771615927261,"version":"3.50.1"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Office of the Assistant Secretary of Defense for Health Affairs","award":["W81XWH-16-2-0019"],"award-info":[{"award-number":["W81XWH-16-2-0019"]}]},{"name":"Spero Therapeutics"},{"DOI":"10.13039\/100012399","name":"HHS | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["IDSEP160030"],"award-info":[{"award-number":["IDSEP160030"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,12,16]]},"abstract":"<jats:p>\n            The activities of azithromycin, fusidic acid, vancomycin, doxycycline, and minocycline were evaluated alone and in combination with SPR741. A total of 202\n            <jats:named-content content-type=\"genus-species\">Escherichia coli<\/jats:named-content>\n            and 221\n            <jats:named-content content-type=\"genus-species\">Klebsiella pneumoniae<\/jats:named-content>\n            isolates were selected, and they included a genome-sequenced subset (\n            <jats:italic>n<\/jats:italic>\n            = 267), which was screened\n            <jats:italic>in silico<\/jats:italic>\n            for \u03b2-lactamase, macrolide-lincosamide-streptogramin (MLS), and tetracycline (\n            <jats:italic>tet<\/jats:italic>\n            ) genes. Azithromycin (&gt;16\u2009mg\/liter), fusidic acid (&gt;64\u2009mg\/liter), vancomycin (&gt;16\u2009mg\/liter), and SPR741 (&gt;8\u2009mg\/liter) showed off-scale MICs when each was tested alone against all isolates.\n          <\/jats:p>","DOI":"10.1128\/aac.00742-20","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T13:57:25Z","timestamp":1602856645000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["<i>In Vitro<\/i>\n            Activity Analysis of a New Polymyxin, SPR741, Tested in Combination with Antimicrobial Agents against a Challenge Set of\n            <i>Enterobacteriaceae<\/i>\n            , Including Molecularly Characterized Strains"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-1137","authenticated-orcid":false,"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6798-7653","authenticated-orcid":false,"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Lister","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5267-4176","authenticated-orcid":false,"given":"Nicole","family":"Cotroneo","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Parr","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":false,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306801"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/664048"},{"key":"e_1_3_3_4_2","unstructured":"CDC. 2019. Antibiotic resistance threats in the United States. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed November 2019."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis942"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2013.00048"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/medsci6010001"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/2049936115621709"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt039"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2019.0198"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_3_12_2","unstructured":"CDC. 2013. Antibiotic resistance threats in the United States 2013. http:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf. Accessed May 2019."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2017.05.014"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183263"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00117-14"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.9.3621-3624.2004"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1368-7646(02)00051-1"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resmic.2018.11.003"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm397"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/32.2.195"},{"key":"e_1_3_3_22_2","volume-title":"M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, eleventh edition. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_23_2","volume-title":"M100Ed28. Performance standards for antimicrobial susceptibility testing: 28th informational supplement","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. M100Ed28. Performance standards for antimicrobial susceptibility testing: 28th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_24_2","unstructured":"EUCAST. 2018. Breakpoint tables for interpretation of MIC's and zone diameters. Version 8.1 May 2018. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_8.0_Breakpoint_Tables.pdf. Accessed January 2018."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz004"},{"key":"e_1_3_3_26_2","volume-title":"M100Ed29. Performance standards for antimicrobial susceptibility testing: 29th informational supplement","author":"CLSI","year":"2019","unstructured":"CLSI. 2019. M100Ed29. Performance standards for antimicrobial susceptibility testing: 29th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_27_2","unstructured":"EUCAST. 2019. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0 January 2019. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf. Accessed January 2019."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00742-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00742-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:49:26Z","timestamp":1645480166000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00742-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,16]]}},"alternative-id":["10.1128\/AAC.00742-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00742-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]},"assertion":[{"value":"2020-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00742-20"}}